Form 4: Cochran Christopher P. reports acquisition/exercise transactions in COEP

(Neutral)

Form Type

Rhea-AI Filing Summary

Cochran Christopher P. reported acquisition or exercise transactions in a Form 4 filing for COEP. The filing lists transactions totaling 8,950 shares at a weighted average price of $10.56 per share. Following the reported transactions, holdings were 8,950 shares.

Insider Trade Summary

Net Buyer: 8,950 shares

Net Buy 2 txns

Insider Cochran Christopher P.

Role Director

Type	Security	Shares	Price	Value
Exercise	Common stock	5,700	$10.56	$60K
Grant/Award	Common Stock	3,250	$0.00	$0.00

Holdings After Transaction: Common Stock — 8,950 shares (Direct)

Footnotes (2)

F1. Represents the exercise price of shares purchased upon exercise of stock options.
F2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/13/2026 - 05:00 PM

FAQ

What insider activity did Coeptis Therapeutics (COEP) report for Christopher P. Cochran?

Christopher P. Cochran acquired more Coeptis Therapeutics shares through an option exercise and a restricted stock grant. He exercised options for 5,700 shares and received 3,250 restricted shares, increasing his direct beneficial ownership to 8,950 common shares.

How many Coeptis Therapeutics (COEP) shares did the director acquire via option exercise?

Christopher P. Cochran acquired 5,700 Coeptis Therapeutics common shares by exercising stock options. The exercise price was $10.56 per share, reflecting the cost embedded in his option agreement rather than an open-market purchase transaction.

What is the nature of the restricted stock grant reported for COEP?

The filing reports a grant of 3,250 shares of restricted stock to Christopher P. Cochran at $0 per share. This grant occurred under an option exchange program, where underwater options were surrendered in return for restricted stock awards.

What does the option exchange program mean in the Coeptis (COEP) Form 4?

The option exchange program allowed the director to surrender underwater stock options in exchange for restricted stock. In this case, Christopher P. Cochran received 3,250 restricted shares, replacing options that had exercise prices above the current stock value.

How many Coeptis Therapeutics (COEP) shares does the director own after these transactions?

After the reported transactions, Christopher P. Cochran beneficially owns 8,950 shares of Coeptis Therapeutics common stock directly. This total reflects both the 5,700 shares from option exercise and the 3,250 restricted shares granted to him.

Was the director’s Coeptis (COEP) restricted stock grant a cash purchase?

No, the restricted stock grant was not a cash purchase. The 3,250 restricted shares were issued at $0 per share as part of an option exchange program, where underwater stock options were surrendered in return for equity awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cochran Christopher P.

(Last)

(First)

(Middle)

105 BRADFORD RD, SUITE 420

(Street)

WEXFORD

15090

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Coeptis Therapeutics Holdings, Inc. [ COEP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	02/11/2026		M		5,700	A	$10.56⁽¹⁾	8,950	D
Common Stock	02/11/2026		A		3,250	A	$0⁽²⁾	8,950	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the exercise price of shares purchased upon exercise of stock options.

2. Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

	/s/ Christopher P. Cochran	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR